MarketWatch (press release) Vectibix was approved in the U.S. in September 2006 as a single agent for the treatment of metastatic colorectal carcinoma with disease progression on or following fluoropyrimidine, oxaliplatin and irinotecan chemotherapy regimens. Approval is based on ... and more »
Watch List News (press release) Treatment with neoadjuvant 5-FU, oxaliplatin, irinotecan , and leucovorin (FOLFIRINOX) followed by chemoradiation shows substantial activity in patients with locally advanced pancreatic cancer, with conversion to surgical resectability with curative ...
PR Newswire (press release) The first Phase 1/2 trial is evaluating PX-866 in combination with the chemotherapeutic agent docetaxel (Taxotere®). The Phase 2 portion of the trial is an open-label, randomized evaluation of the antitumor activity and safety of PX-866 administered at ...
PR Newswire (press release) The authors concluded that the combination of REOLYSIN and FOLFIRI was safe and well tolerated and resulted in disease control in the majority of evaluable patients, including patients that had previously progressed on Irinotecan ;. Clinical Trial ... and more »
Sacramento Bee Vectibix was approved in the U.S. in September 2006 as a single agent for the treatment of metastatic colorectal carcinoma with disease progression on or following fluoropyrimidine, oxaliplatin and irinotecan chemotherapy regimens. Approval is based on ... and more »
